Single-Cell Atlas Reveals DLL3 as a Drug Target in Aggressive Cervical Cancer
A single-cell multi-omic atlas of neuroendocrine carcinoma of the cervix identifies DLL3 as a driver of immune evasion and validates ...
A single-cell multi-omic atlas of neuroendocrine carcinoma of the cervix identifies DLL3 as a driver of immune evasion and validates ...
A phase 1b study presented at the IASLC 2026 World Conference on Lung Cancer found that subcutaneous tarlatamab was well ...
The randomized Phase 2 DeLLphi-309 study found that extended-interval tarlatamab dosing every three or four weeks produced efficacy, safety and ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine